Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging double-blind study of SSR240600C in women with overactive bladder
2007-004126-24Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of burapitant in overactive bladder (OAB) and urge incontinence (5 arms), sponsored by Sanofi. Primary endpoint: Change in number of micturitions per 24 hours. Started Sep 2007; status: completed.
02
Drugs
burapitant
03
Conditions
overactive bladder (OAB)urge incontinence
Beyond the preview
Go deeper on 2007-004126-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004126-24.